Is IL-6 inhibition an option in patients who are going to be rechallenged with checkpoint inhibitors after previously developing ICI-mediated temporal arteritis?

There are reports of using IL-6R inhibition in combination with checkpoint inhibitor therapy in other scenarios (e.g. inflammatory arthritis, cytokine release syndrome). So this would be a reasonable consideration if the oncologist feels strongly that further ICI therapy is beneficial.

Yes, using IL-6 drugs is a good option for the patient with GCA post ICI.

I think theoretically we should be able to continue immunotherapy and biologic therapy such as tocilizumab, but we do not have evidence and insurance companies have not been very amenable. The goal of my research is to ensure ...